Patient Gateway

RSS Feed

MHRA approves lurbinectedin for adults with extensive-stage small-cell lung cancer

Efficacy and safety of primary granulocyte colony-stimulating factor prophylaxis in patients with small-cell lung cancer receiving first-line platinum–etoposide plus a programmed death-ligand 1 inhibitor: A multicenter retrospective observational study

GSK PLC Presents First Global Data For Ris-Rez In Extensive-Stage Small Cell Lung Cancer

Jefferies backs GSK with 2,500p target after positive lung cancer drug results

GSK’s Ris-Rez shows 61% response rate in small cell lung cancer trial By Investing.com

Ris-Rez shows 61% response rate in first global small cell lung cancer data

GSK lung cancer treatment data shows "positive anti-tumour activity"

GSK Reveals Positive Early Data For Ris-Rez In Extensive-stage Small Cell Lung Cancer

GSK PLC - Ris-Rez positive early data in lung cancer

Ris-Rez positive early data in lung cancer